Literature DB >> 11911823

FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses.

Nadine Barnes1, Amanda L Gavin, Peck Szee Tan, Patricia Mottram, Frank Koentgen, P Mark Hogarth.   

Abstract

The inactivation of the mouse high-affinity IgG Fc receptor FcgammaRI resulted in a wide range of defects in antibody Fc-dependent functions. These studies showed the primary importance of FcgammaRI in endocytosis of monomeric IgG, kinetics, and extent of phagocytosis of immune complexes, in macrophage-based ADCC, and in immune complex-dependent antigen presentation to primed T cells. In the absence of FcgammaRI, antibody responses were elevated, implying the removal of a control point by the deletion of FcgammaRI. In addition, FcR-gamma chain-deficient mice were found to express partially functional FcgammaRI. Thus, FcgammaRI is an early participant in Fc-dependent cell activation and in the development of immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11911823     DOI: 10.1016/s1074-7613(02)00287-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  62 in total

1.  MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I.

Authors:  Ting Xie; Jiurong Liang; Ningshan Liu; Qingguo Wang; Yuhang Li; Paul W Noble; Dianhua Jiang
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 2.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

3.  Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients.

Authors:  Patricia A Taylor; Michael J Ehrhardt; Matthew M Roforth; Jessica M Swedin; Angela Panoskaltsis-Mortari; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2006-10-03       Impact factor: 22.113

4.  Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.

Authors:  Judith M H de Jong; Danita H Schuurhuis; Andreea Ioan-Facsinay; Mick M Welling; Marcel G M Camps; Ellen I H van der Voort; Tom W J Huizinga; Ferry Ossendorp; J Sjef Verbeek; René E M Toes
Journal:  Immunology       Date:  2006-09-21       Impact factor: 7.397

5.  Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.

Authors:  Robert Brodzik; Magdalena Glogowska; Katarzyna Bandurska; Monika Okulicz; Deepali Deka; Kisung Ko; Joke van der Linden; Jeanette H W Leusen; Natalia Pogrebnyak; Maxim Golovkin; Zenon Steplewski; Hilary Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-23       Impact factor: 11.205

6.  FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.

Authors:  Falk Nimmerjahn; Anja Lux; Heike Albert; Melissa Woigk; Christian Lehmann; Diana Dudziak; Patrick Smith; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

7.  Regulation of FcRγ function by site-specific serine phosphorylation.

Authors:  Spandan Shah; Andrew W Gibson; Chuanyi Ji; Eric Darrington; James Mobley; Kyoko Kojima; Jeffrey C Edberg; Robert P Kimberly
Journal:  J Leukoc Biol       Date:  2016-09-14       Impact factor: 4.962

Review 8.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

9.  Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus.

Authors:  Taeg S Kim; Stanley Perlman
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

10.  IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R.

Authors:  Christopher E Martin; Ester M M van Leeuwen; Se Jin Im; Derry C Roopenian; Young-Chul Sung; Charles D Surh
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.